Laurus Labs Invests ₹40 crore in subsidiary Laurus Bio
By Ankur Chandra | Updated at: Jan 14, 2026 12:48 PM IST
Hyderabad, June 26, 2025: Laurus Labs Ltd (NSE: LAURUSLABS | BSE: 540222) has announced a fresh investment in its subsidiary Laurus Bio Private Limited through a preferential allotment of Series A2 preference shares. The investment complies with Regulation 30(7) of SEBI (LODR) Regulations, 2015.
The step is in alignment with Laurus Labs’ planned investment in Laurus Bio, as announced on December 6, 2024, to further strengthen Laurus Labs’ footprint in the biotech segment. The investment involves 15,414 shares and is worth ₹39.99 crore.
As of 1:16 PM, the shares of Laurus Labs Ltd were trading at ₹678.75, up by 1.31% for the day, reflecting continued positive momentum in the afternoon session.
Investment Details
The company acquired 15,414 Series A2 Compulsorily Convertible Preference Shares (CCPS) of Laurus Bio at a face value of ₹100 and a premium of ₹25,850.02 per share, bringing the total transaction value to ₹39,99,93,608.28.
This move follows Laurus Labs’ earlier disclosure on December 6, 2024, regarding its intent to invest in Laurus Bio and is in accordance with Regulation 30(7) of SEBI (LODR) Regulations, 2015.
Investment Breakdown:
| Particulars | Details |
|---|---|
| Number of shares acquired | 15,414 |
| Face value per share | ₹100 |
| Premium per share | ₹25,850.02 |
| Total investment | ₹39,99,93,608.28 |
| Mode of allotment | Private Placement cum Preferential Allotment |
| Share class | Series A2 Compulsorily Convertible Preference Shares |
Strategic Significance
The capital infusion underscores Laurus Labs’ long-term commitment to scaling its biotech capabilities through Laurus Bio, which plays a strategic role in the company’s future growth roadmap in high-value biologics and fermentation-based platforms.
Market Outlook
The preferential allotment has bolstered investor sentiment, driving a modest uptick in Laurus Labs’ shares as markets welcomed the biotech expansion. With this strategic infusion reinforcing its high-value biologics roadmap, near-term performance should benefit from enhanced growth prospects and renewed market confidence.
About the Company
Laurus Labs Ltd is a publicly listed pharmaceutical and biotechnology company headquartered in Hyderabad, India. It operates across APIs, formulations, custom synthesis, and biotechnology. The company is listed on both BSE and NSE and holds a strong presence in global markets with a focus on innovation-led manufacturing.
REF: https://nsearchives.nseindia.com/corporate/LAURUSLABS_26062025115324_UpdateOnBio26062025.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
